Twinbeech Capital LP Denali Therapeutics Inc. Transaction History

Twinbeech Capital LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$15.83 - $23.35 $2.17 Million - $3.19 Million	136,784 Added 337.07%	177,364 $3.64 Million
Q4 2023 Feb 14, 2024	BUY	$16.2 - $23.18 $657,396 - $940,644	40,580 New	40,580 $870,000
Q1 2023 May 15, 2023	BUY	$21.91 - $32.67 $3.27 Million - $4.88 Million	149,302 New	149,302 $3.44 Million
Q2 2022 Aug 15, 2022	SELL	$20.88 - $35.19 $376,800 - $635,038	-18,046 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$29.0 - $47.27 $523,334 - $853,034	18,046 New	18,046 $581,000

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.